Fourth dose of Pfizer mRNA COVID vaccine protecting in opposition to variants and symptomatic an infection
  • Reading time:5 min(s) read

In a current research revealed on the preprint server medRxiv*, researchers consider the efficacy of three- and four-dose regimens of a messenger ribonucleic acid (mRNA)-based coronavirus illness 2019 (COVID-19) vaccine in lowering the danger of symptomatic extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) an infection.

Study: Correlates of safety for booster doses of the BNT162b2 vaccine. Image Credit: Zubada /


As of July 20, 2022, SARS-CoV-2 has contaminated over 566 million people and triggered nearly 6.4 million deaths worldwide. Despite the success of worldwide vaccination campaigns in lowering COVID-19-related mortality and morbidity, rising viral variants and declining vaccine efficacy have perpetuated new an infection waves.

Considering the sharp rise in vaccine breakthrough instances, many public well being businesses have authorized further vaccine doses to the overall inhabitants. These initiatives have been supported by rising proof demonstrating {that a} third vaccine dose is extremely efficient in inducing a sturdy neutralizing antibody response, in addition to the danger of extreme COVID-19 and hospitalization.

In Israel, a 3rd dose of the Pfizer/BioNTech mRNA-based COVID-19 vaccine was first launched in August 2021 to manage the unfold of the SARS-CoV-2 Delta variant. Soon after, a fourth vaccine dose was launched in January 2022 to fight the exponential rise in Omicron instances all through the nation. A fourth COVID-19 vaccine dose has been prioritized for immunocompromised sufferers, healthcare staff, and aged folks aged 60 years and above.

About the research

The present research included 608 healthcare staff from 4 completely different medical facilities in Israel. Of all enrolled individuals, 365 acquired three vaccine doses, and 243 acquired 4 vaccine doses.

During the 90-day follow-up interval, the incidence of SARS-CoV-2 an infection, in addition to vaccine-induced antibody responses, have been decided at enrollment and at days 30 and 90 post-enrollment. The common follow-up days have been 76 and 75 for the four-dose and three-dose teams, respectively.

Both immunoglobulin G (IgG)- and IgA-specific antibodies focusing on a number of SARS-CoV-2 antigens have been measured utilizing blood samples collected from the individuals.

Study findings

About 45% and 30% of individuals from the three- and four-dose teams, respectively, developed SARS-CoV-2 an infection in the course of the 90-day follow-up interval.

At day 30 post-enrollment, considerably larger titers of each IgG and IgA antibodies in opposition to the unique pressure of SARS-CoV-2 have been noticed in four-dose vaccinated individuals in comparison with that at enrollment. Moreover, four-dose vaccinated individuals confirmed considerably larger IgA antibodies in opposition to SARS-CoV-2 variants.

In three-dose vaccinated individuals, a decline in IgG titers in opposition to the wild-type SARS-CoV-2 pressure, in addition to IgA and IgG titers in opposition to SARS-CoV-2 variants, was noticed at day 30 post-enrollment.

A major induction in neutralizing antibody titers in opposition to the wild-type, Delta, and Omicron strains was noticed in four-dose vaccinated individuals at day 30 post-enrollment.

In SARS-CoV-2-infected individuals, a major improve in antibody ranges was noticed at day 30, no matter the variety of vaccine doses acquired. However, a discount of about 37% within the danger of symptomatic an infection was noticed amongst individuals who had acquired 4 vaccine doses.

The baseline IgA response to the wild-type SARS-CoV-2 pressure, in addition to its variants, confirmed the very best correlation with the danger of an infection in four-dose vaccinated individuals at day 30. Comparatively, the baseline IgG response to variants with mutations within the spike receptor-binding area (RBD) confirmed a major correlation with the danger of an infection in three-dose vaccinated individuals throughout the complete follow-up interval.

Upon evaluating four-dose vaccinated individuals with low or excessive antibody ranges after the third vaccine dose, a considerably larger variety of infections have been noticed in individuals with low antibody ranges as in comparison with these with excessive antibody ranges.

Vaccination with the 4th dose elicited binding and neutralizing antibodies in opposition to SARS-CoV-2. Responses of uninfected individuals have been analyzed at enrollment (day 0) and at day 30 utilizing a number of serological assays (A) IgG and IgA magnitude to antigens from the Wuhan pressure and SARS-COV-2 variants. Antigen microarrays noticed with RBD, S1 and spike proteins of the Wuhan vaccine pressure and a number of different variants of concern have been used to measure the magnitude of responses at day 0 (enrollment) and day 30 post-enrollment. (B) Spider plots depicting the enrollment (pink) and day 30 (inexperienced) antibody ranges to Wuhan antigens (inexperienced), variants of concern (pink) and RBD mutants (blue). The common normalized magnitude to every antigen is plotted in people that acquired 3 or 4 doses. (C) IgG and IgA anti-RBD ELISA binding titers for a subset of 74 individuals (D) Live-virus neutralization EC50 titers of the identical people in panel C. (E) Pseudovirus neutralization titers of uninfected people that acquired 4 (n=30, blue). (F) Cumulative incidence of SARS-CoV-2 infections in individuals receiving three (n=365) vs. 4 doses (n=243) of the Pfizer vaccine. Four doses of the vaccine considerably decreased an infection charges at day +30 (HR=0.55, p=0.002) and throughout all interim followup time (HR=0.63, p=0.003) as in comparison with three doses. * p < 0.05; ** p < 0.001; *** p < 0.0001; **** p < 0.00001.

Study significance

Combinations of IgA and IgG antibody ranges have been discovered to be answerable for offering safety in opposition to symptomatic SARS-CoV-2 an infection following receipt of three and 4 doses of COVID-19 vaccines. Notably, a fourth vaccine dose was discovered to cut back the danger of symptomatic an infection by 37%.

The present research additionally highlights that people with a low antibody response after the third vaccine dose are at a better danger of creating symptomatic an infection, regardless of receiving the fourth vaccine dose.

*Important discover

medRxiv publishes preliminary scientific stories that aren’t peer-reviewed and, due to this fact, shouldn’t be considered conclusive, information scientific observe/health-related habits, or handled as established info.

Journal reference:

  • Hertz, T., Levy, S., Ostrovsky, D., et al. (2022). Correlates of safety for booster doses of the BNT162b2 vaccine. medRxiv. doi:10.1101/2022.07.16.22277626. material/10.1101/2022.07.16.22277626v1

If you are interested in working in a distraction free environment, visit our site Blissful Noises where we provide various sounds and features to help you focus or relax.